Skip to search formSkip to main contentSkip to account menu

milameline

Known as: 1,2,5,6-tetrahydro-1-methyl-3-pyridinecarboxaldehyde O-methyloxime monohydrochloride 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

CI 979

Broader (2)

DihydropyridinesOximes

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Acute modulation of the cholinergic system in the mouse brain detected by pharmacological resting-state functional MRI
Highly Cited
2005
Highly Cited
2005
Pharmacologic Interactions between the Muscarinic Cholinergic and Dopaminergic Systems in the Modulation of Prepulse Inhibition in Rats
Prepulse inhibition (PPI) of the acoustic startle reflex is a sensorimotor gating process known to be deficient in a number of… 
Highly Cited
2003
Highly Cited
2003
MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD
Objective: To assess the feasibility of using MRI measurements as a surrogate endpoint for disease progression in a therapeutic… 
Highly Cited
2000
Highly Cited
2000
Interrater Reliability of the Clinical Dementia Rating in a Multicenter Trial
OBJECTIVE: To test the interrater reliability of the Clinical Dementia Rating (CDR) in a multicenter clinical trial. 
Review
1999
Review
1999
Acetylcholinesterase inhibitors in Alzheimer's disease.
Alzheimer’s Disease (AD) is the most common single cause of dementia in our ageing society. Traditionally thought of as an… 
Highly Cited
1999
Highly Cited
1999
Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats.
The purpose of our studies was to determine the effects of muscarinic receptor agonists on conditioned avoidance responding in… 
1999
1999
In vitro characterisation of the muscarinic receptor partial agonist, sabcomeline, in rat cortical and heart membranes.
1999
1999
Combining tacrine with milameline reverses a scopolamine-induced impairment of continuous performance in rhesus monkeys
Abstract  Rationale: Cholinomimetic therapy in Alzheimer’s disease (AD) has been hampered by narrow efficacious dose ranges and… 
1999
1999
Muscarinic Receptor Agonists in Alzheimer’s Disease
Research into and development of selective muscarinic receptor agonists for the treatment of Alzheimer’s disease is based on the… 
Highly Cited
1998
Highly Cited
1998
Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License